These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 31785545)

  • 1. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP; Zonder JA
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the ubiquitin proteasome system in lymphoma.
    Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.
    Tyrna P; Procyk G; Szeleszczuk Ł; Młynarczuk-Biały I
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
    Kuhn DJ; Orlowski RZ; Bjorklund CC
    Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Ishii Y; Waxman S; Germain D
    Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
    Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
    Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positioning of proteasome inhibitors in therapy of solid malignancies.
    Roeten MSF; Cloos J; Jansen G
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):227-243. PubMed ID: 29184971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer.
    Rohondia SO; Ahmed ZSO; Dou QP
    Curr Cancer Drug Targets; 2020; 20(6):392-409. PubMed ID: 32101123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.
    Johnson DE
    Endocr Relat Cancer; 2015 Feb; 22(1):T1-17. PubMed ID: 24659480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells.
    Yerlikaya A; Kanbur E
    Curr Drug Targets; 2020; 21(13):1313-1325. PubMed ID: 32448101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
    Kegyes D; Gulei D; Drula R; Cenariu D; Tigu B; Dima D; Tanase A; Badelita S; Buzoianu AD; Ciurea S; Ghiaur G; Terpos E; Ciechanover A; Einsele H; Tomuleasa C
    Blood Rev; 2023 Sep; 61():101100. PubMed ID: 37291017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment.
    Zhang L; Wu M; Su R; Zhang D; Yang G
    Recent Pat Anticancer Drug Discov; 2022; 17(3):268-283. PubMed ID: 34856915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors.
    Teicher BA; Tomaszewski JE
    Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
    Wang H; Guan F; Chen D; Dou QP; Yang H
    Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.